Ligand Pharmaceuticals Enters Material Definitive Agreement
Ticker: LGNZZ · Form: 8-K · Filed: Feb 25, 2025 · CIK: 886163
| Field | Detail |
|---|---|
| Company | Ligand Pharmaceuticals Inc (LGNZZ) |
| Form Type | 8-K |
| Filed Date | Feb 25, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, definitive-agreement, sec-filing
Related Tickers: LGND
TL;DR
Ligand Pharma just signed a big deal, details to come.
AI Summary
Ligand Pharmaceuticals Inc. announced on February 24, 2025, that it entered into a material definitive agreement. The company, headquartered in San Diego, California, filed a Form 8-K with the SEC detailing this agreement. Further specifics regarding the nature and terms of the agreement are expected to be disclosed.
Why It Matters
This filing indicates a significant new contract or partnership for Ligand Pharmaceuticals, which could impact its future revenue streams and strategic direction.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the lack of immediate detail necessitates caution.
Key Players & Entities
- Ligand Pharmaceuticals Inc. (company) — Registrant
- February 24, 2025 (date) — Date of earliest event reported
- San Diego, California (location) — Company headquarters
- 858-550-7500 (phone_number) — Registrant's Telephone Number
FAQ
What is the nature of the material definitive agreement entered into by Ligand Pharmaceuticals?
The filing states that Ligand Pharmaceuticals Inc. entered into a material definitive agreement on February 24, 2025, but the specific details of this agreement are not provided in this initial 8-K filing.
When was this Form 8-K filed with the SEC?
This Form 8-K was filed as of February 25, 2025.
What is Ligand Pharmaceuticals' primary business sector?
Ligand Pharmaceuticals Inc. operates in the Pharmaceutical Preparations sector, with the Standard Industrial Classification code 2834.
Where is Ligand Pharmaceuticals' principal executive office located?
Ligand Pharmaceuticals' principal executive offices are located at 555 Heritage Drive, Suite 200, Jupiter, Florida 33458.
What is the Commission File Number for Ligand Pharmaceuticals?
The Commission File Number for Ligand Pharmaceuticals Inc. is 001-33093.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 25, 2025 regarding LIGAND PHARMACEUTICALS INC (LGNZZ).